Hoth Therapeutics Inc (HOTH)

$1.28 -0.02 (-1.54%)
Market Cap 16.91M
Revenue (ttm) 0.00
Net Income (ttm) -8.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 77,500
Avg Vol 1,379,230
Day's Range N/A - N/A
Shares Out 13.21M
Stochastic %K 23%
Beta 0.67
Analysts Strong Sell
Price Target $4.50

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for th...

Industry: Biotechnology
Sector: Healthcare
Phone: (646) 756-2997
Address:
1177 Avenue of the Americas, Suite 5066 5th Floor, New York, United States
Tino321
Tino321 Jul. 28 at 4:34 AM
$HOTH let’s get rich this week folks 🫣😂
0 · Reply
Pratik2024
Pratik2024 Jul. 27 at 2:53 AM
$GFAI $HOTH $KULR $MWYN $AREC Back from vacation. Did I miss anything?
1 · Reply
Phantom_OfThe_Retrrrd
Phantom_OfThe_Retrrrd Jul. 26 at 11:03 PM
$OLB $OLB reminds me of the quiet phase before $HOTH exploded last year—no attention, just coiling tight.
0 · Reply
canadianpennystockhunter
canadianpennystockhunter Jul. 26 at 10:47 PM
$HOTH
0 · Reply
Biotechs5454
Biotechs5454 Jul. 26 at 10:37 PM
$HOTH Played this one for years. Too many bs PRs though. Has always bothered me. We need data on the double blind portion of HT-001, not PRs about crap that is 10 years away and HOTH is funding. Still feel we are at an inflection point so holding until real news.
1 · Reply
FastBull
FastBull Jul. 25 at 2:55 PM
$HOTH when under $1?
0 · Reply
RaphaelRapoport
RaphaelRapoport Jul. 23 at 3:22 PM
$HOTH let’s get this train back to $1.6
0 · Reply
JarvisFlow
JarvisFlow Jul. 23 at 11:30 AM
D. Boral Capital has updated their rating for Hoth Therapeutics ( $HOTH ) to Buy with a price target of 5.
1 · Reply
Tino321
Tino321 Jul. 23 at 6:14 AM
$HOTH 🙏
0 · Reply
MGeronimo
MGeronimo Jul. 23 at 2:47 AM
$HOTH IN AT 1.30
0 · Reply
Latest News on HOTH
Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Jul 22, 2025, 8:19 AM EDT - 5 days ago

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 25, 2025, 8:27 AM EDT - 4 weeks ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 24, 2025, 10:36 AM EDT - 4 weeks ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 23, 2025, 8:03 AM EDT - 4 weeks ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 1:34 PM EDT - 5 weeks ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 18, 2025, 8:22 AM EDT - 5 weeks ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 16, 2025, 8:00 AM EDT - 5 weeks ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 12, 2025, 9:17 AM EDT - 6 weeks ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 11, 2025, 8:28 AM EDT - 6 weeks ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 7 weeks ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

May 12, 2025, 7:30 AM EDT - 2 months ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 17, 2025, 8:01 AM EDT - 3 months ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 15, 2025, 8:19 AM EDT - 3 months ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 8:02 AM EDT - 4 months ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Apr 2, 2025, 7:58 AM EDT - 4 months ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 31, 2025, 4:45 PM EDT - 4 months ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 26, 2025, 8:02 AM EDT - 4 months ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 18, 2025, 8:06 AM EDT - 4 months ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Mar 10, 2025, 8:02 AM EDT - 4 months ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Mar 5, 2025, 1:40 PM EST - 5 months ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Mar 4, 2025, 8:16 AM EST - 5 months ago

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Feb 10, 2025, 8:22 AM EST - 5 months ago

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jan 24, 2025, 8:29 AM EST - 6 months ago

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Jan 21, 2025, 8:29 AM EST - 6 months ago

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Jan 17, 2025, 8:29 AM EST - 6 months ago

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Jan 8, 2025, 1:27 PM EST - 7 months ago

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Jan 7, 2025, 11:53 AM EST - 7 months ago

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Jan 7, 2025, 8:29 AM EST - 7 months ago

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Dec 26, 2024, 7:58 AM EST - 7 months ago

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 20, 2024, 7:38 AM EST - 8 months ago

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Oct 29, 2024, 12:43 PM EDT - 9 months ago

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Oct 15, 2024, 6:38 AM EDT - 10 months ago

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Sep 17, 2024, 7:57 AM EDT - 11 months ago

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Sep 5, 2024, 10:32 AM EDT - 11 months ago

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Sep 5, 2024, 8:03 AM EDT - 11 months ago

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Aug 15, 2024, 8:04 AM EDT - 1 year ago

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Jul 16, 2024, 8:31 AM EDT - 1 year ago

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Jun 10, 2024, 8:11 AM EDT - 1 year ago

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

May 1, 2024, 8:00 AM EDT - 1 year ago

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

Mar 27, 2024, 2:00 PM EDT - 1 year ago

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Mar 27, 2024, 8:27 AM EDT - 1 year ago

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Mar 19, 2024, 8:21 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

Feb 29, 2024, 8:38 AM EST - 1 year ago

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

Feb 26, 2024, 8:11 AM EST - 1 year ago

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

Feb 13, 2024, 11:45 AM EST - 1 year ago

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

Jan 18, 2024, 8:20 AM EST - 1 year ago

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies

Dec 5, 2023, 8:33 AM EST - 1 year ago

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT

Nov 14, 2023, 8:37 AM EST - 1 year ago

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT

Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023

Nov 10, 2023, 8:00 AM EST - 1 year ago

Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023

Tino321
Tino321 Jul. 28 at 4:34 AM
$HOTH let’s get rich this week folks 🫣😂
0 · Reply
Pratik2024
Pratik2024 Jul. 27 at 2:53 AM
$GFAI $HOTH $KULR $MWYN $AREC Back from vacation. Did I miss anything?
1 · Reply
Phantom_OfThe_Retrrrd
Phantom_OfThe_Retrrrd Jul. 26 at 11:03 PM
$OLB $OLB reminds me of the quiet phase before $HOTH exploded last year—no attention, just coiling tight.
0 · Reply
canadianpennystockhunter
canadianpennystockhunter Jul. 26 at 10:47 PM
$HOTH
0 · Reply
Biotechs5454
Biotechs5454 Jul. 26 at 10:37 PM
$HOTH Played this one for years. Too many bs PRs though. Has always bothered me. We need data on the double blind portion of HT-001, not PRs about crap that is 10 years away and HOTH is funding. Still feel we are at an inflection point so holding until real news.
1 · Reply
FastBull
FastBull Jul. 25 at 2:55 PM
$HOTH when under $1?
0 · Reply
RaphaelRapoport
RaphaelRapoport Jul. 23 at 3:22 PM
$HOTH let’s get this train back to $1.6
0 · Reply
JarvisFlow
JarvisFlow Jul. 23 at 11:30 AM
D. Boral Capital has updated their rating for Hoth Therapeutics ( $HOTH ) to Buy with a price target of 5.
1 · Reply
Tino321
Tino321 Jul. 23 at 6:14 AM
$HOTH 🙏
0 · Reply
MGeronimo
MGeronimo Jul. 23 at 2:47 AM
$HOTH IN AT 1.30
0 · Reply
ericschu
ericschu Jul. 23 at 12:54 AM
$HOTH come on...
0 · Reply
canadianpennystockhunter
canadianpennystockhunter Jul. 22 at 8:12 PM
$HOTH
0 · Reply
WallStreetReporter
WallStreetReporter Jul. 22 at 1:41 PM
$HOTH 🚀🚀🚀 https://finance.yahoo.com/news/hoth-therapeutics-signs-va-research-121900563.html
1 · Reply
MrTicker
MrTicker Jul. 22 at 1:18 PM
$HOTH BRIEF-Hoth Therapeutics Signs VA Research Deal To Advance GDNF As Breakthrough Therapy For Obesity And Fatty Liver REUTERS 8:17 AM ET 7/22/2025
0 · Reply
MHM7700
MHM7700 Jul. 22 at 12:52 PM
42% total win on traded capital for the morning on $IVF, $ICU and $HOTH. all trades caught on live in discord with my team and posted here slightly later with timestamps of my entires along with PTs and SLs. no greed....just compounding gains consistently everyday. will come back for options once the market opens.
1 · Reply
MHM7700
MHM7700 Jul. 22 at 12:50 PM
13% win on the $HOTH trade. PT1 @ 1.40 (25% covered), PT2 @ 1.35 (75% covered). PT3 never hit and will not spend more time on this. https://stocktwits.com/MHM7700/message/621897570
0 · Reply
Proteus63
Proteus63 Jul. 22 at 12:45 PM
$HOTH https://ir.hoththerapeutics.com/
0 · Reply
FastBull
FastBull Jul. 22 at 12:33 PM
$HOTH I’m all for PR but isn’t this recycled news?
2 · Reply
Go_Stock_yourself
Go_Stock_yourself Jul. 22 at 12:25 PM
$HOTH "Hoth Therapeutics partners with VA for obesity therapy study" https://ca.investing.com/news/assorted/hoth-therapeutics-partners-with-va-for-obesity-therapy-study-432SI-4112064
0 · Reply
MHM7700
MHM7700 Jul. 22 at 12:21 PM
$HOTH short @ 1.54 PT1 @ 1.40, PT2 @ 1.35 and PT3 @ 1.30 (or ride the trend). SL @ 1.75.
0 · Reply
premarketmaker
premarketmaker Jul. 22 at 12:21 PM
$HOTH $1.65+ for the squeeze
0 · Reply
MrTicker
MrTicker Jul. 22 at 12:21 PM
$HOTH Hoth Therapeutics Announces CRADA With U.S. Department Of Veterans Affairs And FAVER To Evaluate GDNF As Metabolic Therapy Targeting Obesity And Hepatic Steatosis BENZINGA 7:20 AM ET 7/22/2025
0 · Reply